THE LONG DAWN

Dispatches / Cancer

The long siege of cancer

Daraxonrasib doubled median survival in previously treated pancreatic cancer, and the FDA approved it

The first drug to strike RAS across its many mutations has crossed from trial to treatment.

ApprovedPeer-reviewed journal

What happened

  • In the phase 3 RASolute 302 trial, 500 people with metastatic pancreatic cancer who had already been treated were randomly assigned to daraxonrasib or chemotherapy.
  • Median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy in the main group (hazard ratio 0.40). Results were published in The New England Journal of Medicine.
  • The FDA approved daraxonrasib (brand name Rasonque, Revolution Medicines) in August 2026 for adults with metastatic pancreatic cancer who have had at least one prior systemic therapy or cannot take multi-drug chemotherapy.

What we don't know yet

  • Serious (grade 3 or higher) side effects were common in both groups: 61.8% with daraxonrasib and 69.6% with chemotherapy.
  • The trial was open-label, so patients and doctors knew which treatment was given.
  • Its use as a first treatment, before chemotherapy, is still being tested.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.